Juvenile dermatomyositis. Juvenile dermatomyositis
Conditions
Interventions
Intervention group: Patients based on Body Surface Area (BSA) treated with the appropriate dose of rituximab (575 mg/m2 in patients with BSA =1.5 m2 and 750 mg/m2 in patients with BSA>1.5 m2), Two dos
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 16 Years
Inclusion criteria
Inclusion criteria: Patient under 16 years old Patients with the diagnosis of dermatomyositis, which is confirmed based on the diagnosis criteria
Exclusion criteria
Exclusion criteria: Presence of concomitant diseases and overlap syndrome Contraindications for rituximab injection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease activity. Timepoint: At the beginning of the intervention (before the start of the intervention), one week, one month, two months, three months, six months and one year after rituximab injection. Method of measurement: Juvenile Dermatomyositis-Disease Activity Score questionnaire, questionnaire of characteristics and information of dermatomyositis patients.;Drug Side Effects. Timepoint: One week, one month, two months, three months, six months and one year after rituximab injection. Method of measurement: Questioning the patient and parents. | — |
Secondary
| Measure | Time frame |
|---|---|
| Daily activity and quality of life. Timepoint: Before starting the intervention, one month, two, three months, six months and one year after drug injection. Method of measurement: Juvenile Dermatomyositis-Disease Activity Score questionnaire, questionnaire of characteristics and information of dermatomyositis. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactPooneh Tabibi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed